Last updated: August 27, 2026
Temsirolimus, marketed as Torisel by Pfizer, is an intravenous mTOR inhibitor approved in the United States for adults with advanced renal cell carcinoma (RCC) with poor-risk prognostic features. Its commercial position has weakened because the drug serves a narrow, older treatment segment, requires intravenous administration, competes with oral targeted therapies and immunotherapies, and has no separately reported revenue stream in Pfizer’s public filings. The product remains clinically relevant in selected RCC cases but is no longer a major growth asset.
What is temsirolimus and how is it used?
Temsirolimus is a rapamycin derivative and selective inhibitor of the mammalian target of rapamycin, or mTOR. It is administered as a 25 mg intravenous infusion once weekly.
The FDA approved Torisel on May 30, 2007, under New Drug Application 022088 for first-line treatment of advanced RCC.[1] The approval was based primarily on a randomized study showing improved overall survival compared with interferon alfa in patients with poor-risk disease.[2]
| Attribute |
Temsirolimus |
| Brand |
Torisel |
| Active ingredient |
Temsirolimus |
| Company |
Pfizer, originally Wyeth |
| Drug class |
mTOR inhibitor |
| Route |
Intravenous infusion |
| Standard dose |
25 mg once weekly |
| Initial U.S. approval |
May 30, 2007 |
| Approved indication |
Advanced RCC with poor-risk features |
| FDA application |
NDA 022088 |
| Biosimilar pathway |
Not applicable |
| Primary commercial market |
Oncology, renal cell carcinoma |
Temsirolimus is converted in vivo to sirolimus, but its regulatory and commercial position differs from that of sirolimus products used in transplantation and drug-eluting stents.
What is the current market position of temsirolimus?
Temsirolimus occupies a small and declining niche in the RCC market. Its original competitive advantage was the survival benefit demonstrated in poor-risk, treatment-naive patients before immune checkpoint inhibitors became standard components of RCC treatment.
The RCC market has shifted toward combinations involving checkpoint inhibitors, vascular endothelial growth factor tyrosine kinase inhibitors, and newer targeted agents. Common competitors include:
- Nivolumab plus ipilimumab
- Pembrolizumab plus axitinib
- Pembrolizumab plus lenvatinib
- Nivolumab plus cabozantinib
- Avelumab plus axitinib
- Cabozantinib
- Axitinib
- Pazopanib
- Sunitinib
These regimens are generally preferred over single-agent temsirolimus in many treatment settings because they offer broader guideline support, oral or combination-based treatment options, or more recent survival data.[3]
How does temsirolimus compare with everolimus?
Temsirolimus and everolimus are both mTOR-pathway inhibitors, but their commercial profiles differ materially.
| Factor |
Temsirolimus |
Everolimus |
| Brand |
Torisel |
Afinitor and other brands |
| Administration |
Intravenous |
Oral |
| Primary RCC role |
Historically first-line poor-risk RCC |
Later-line RCC and multiple indications |
| Broader indications |
Limited |
RCC, breast cancer, neuroendocrine tumors, tuberous sclerosis |
| Commercial reach |
Narrow |
Broad |
| Generic competition |
Market-specific |
More established generic exposure |
| Current strategic value |
Low to moderate niche value |
Broader oncology and specialty portfolio value |
Everolimus benefits from multiple approved indications, while temsirolimus is concentrated in one increasingly competitive disease area.
When did temsirolimus lose market exclusivity?
Temsirolimus no longer has the market protection associated with a newly approved oncology drug. FDA chemical-drug exclusivity from the 2007 approval would have expired in the early 2010s, subject to any applicable pediatric extension or other regulatory adjustment.[4]
The commercial impact of exclusivity loss has been moderated by several factors:
- Torisel is an injectable oncology product with relatively low unit demand.
- Generic manufacturers may face sterile-manufacturing and commercial-scale barriers.
- RCC treatment has moved toward newer therapies, reducing the value of late generic entry.
- Public sources do not establish a material, separately reported current revenue stream for Torisel.
Regulatory exclusivity and patent protection are separate. FDA exclusivity controls certain approval timing rights, while patent protection depends on the claims, patent-term adjustments, terminal disclaimers, and Orange Book listing status.
What patents protect temsirolimus?
Temsirolimus was developed from rapamycin derivative chemistry and related formulation work. Its historical patent estate included compound, derivative, formulation, and manufacturing claims. The practical value of that estate has declined because the product was approved more than 15 years ago and the key commercial protection periods have substantially matured.
A current patent analysis must distinguish among:
- Patents directed to temsirolimus as a chemical entity
- Patents covering injectable formulations
- Patents covering solvents, excipients, or concentrate-and-diluent systems
- Manufacturing or purification patents
- Method-of-use patents for RCC
- Patents that expired before or after FDA approval
- Orange Book-listed patents versus broader patent-family rights
The FDA Orange Book is the controlling public source for patents submitted for an approved drug application. Patent records should be checked against NDA 022088 rather than relying on third-party drug databases.[5]
What formulations are protected by temsirolimus patents?
Torisel is supplied as an injection kit involving a temsirolimus concentrate and a diluent. Formulation and container-closure claims can be commercially relevant because injectable products must satisfy sterility, stability, compatibility, and particulate-matter requirements.
The formulation barrier is more important than the active ingredient itself for a potential generic entrant. A competitor may need to demonstrate:
- Equivalent concentration and dosing flexibility
- Comparable stability after dilution
- Compatible infusion materials
- Sterility and particulate control
- Comparable pharmacokinetic performance
- Adequate container-closure integrity
These requirements can delay or raise the cost of entry even where core compound patents have expired.
What is the Orange Book status of Torisel?
Torisel is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations database under NDA 022088. The Orange Book should be used to determine the active status of any listed patents and regulatory exclusivities.[5]
The business significance of the listing is limited unless a listed patent remains enforceable and is relevant to a proposed abbreviated new drug application. A generic applicant could challenge listed patents through a Paragraph IV certification or certify that the patents have expired, depending on the current Orange Book record.
What Paragraph IV challenges affect temsirolimus?
No widely reported, commercially significant Paragraph IV litigation involving a major U.S. temsirolimus generic has established a high-profile market outcome comparable with major blockbuster oncology products. The absence of a prominent challenge does not eliminate generic risk. It indicates that the addressable market may be too small, the regulatory pathway may be technically difficult, or the remaining commercial value may not justify litigation expense.
A Paragraph IV applicant would face several possible outcomes:
| Scenario |
Likely commercial effect |
| No generic filing |
Continued branded or limited-supply market |
| First generic approval without litigation |
Rapid price erosion in a small market |
| Paragraph IV litigation |
Entry delay until settlement, judgment, or patent expiry |
| At-risk launch |
Potential damages exposure and injunction risk |
| Limited hospital contracting |
Modest volume transfer despite approval |
What is the FDA regulatory status of temsirolimus?
The FDA approved temsirolimus for advanced RCC with poor-risk prognostic features. Its label includes warnings relating to hypersensitivity reactions, hyperglycemia, hyperlipidemia, infections, pneumonitis, renal failure, bowel perforation, wound-healing complications, and embryo-fetal toxicity.[1]
The drug’s regulatory limitations include:
- Intravenous delivery
- Weekly infusion-center utilization
- Need for premedication and monitoring
- Toxicity management
- Narrow approved indication
- Competition from newer first-line RCC regimens
There is no biosimilar pathway for temsirolimus because it is a small-molecule drug rather than a biologic. Any competition would arise through an ANDA, a 505(b)(2) application, or a full NDA route, depending on the product’s formulation and clinical differences.
How has temsirolimus revenue changed over time?
Pfizer does not generally report Torisel as a separate current revenue line in its consolidated public financial statements. Revenue is aggregated into broader product or therapeutic-area categories. As a result, an audited annual revenue series for temsirolimus cannot be derived directly from Pfizer’s filings.
The financial trajectory can be described in phases:
| Period |
Commercial trajectory |
| 2007-2010 |
Launch and adoption in poor-risk first-line RCC |
| 2011-2015 |
Pressure from oral targeted therapies and broader RCC competition |
| 2016-2020 |
Further displacement by checkpoint inhibitors and combination regimens |
| 2021 onward |
Mature niche product with limited growth potential |
Torisel’s peak commercial value was likely reached well before the current immuno-oncology era. Pfizer’s larger oncology products, including Ibrance, Xtandi, Inlyta, and other portfolio assets, have made Torisel financially immaterial at the group level.
The principal revenue risks are treatment substitution, reduced physician preference, hospital formulary pressure, lower treatment duration, and generic or therapeutic competition. Price increases could offset some unit-volume erosion, but they would not reverse the underlying decline in clinical relevance.
Which companies could challenge temsirolimus commercially?
The most significant competitors are not necessarily generic manufacturers. They are companies selling treatments that displace temsirolimus in RCC treatment pathways.
| Company |
Competing products or platforms |
Competitive mechanism |
| Bristol Myers Squibb |
Opdivo, Yervoy |
Immune checkpoint combinations |
| Merck |
Keytruda combinations |
First-line RCC penetration |
| Exelixis |
Cabometyx |
Targeted therapy and combination use |
| Pfizer |
Inlyta |
Internal portfolio substitution |
| Novartis |
Afinitor |
Same pathway, oral formulation |
| Eisai and Merck |
Lenvima plus Keytruda |
Combination efficacy |
| Roche |
Tecentriq, where relevant |
Immunotherapy competition |
Pfizer faces internal cannibalization risk because its broader oncology portfolio has stronger commercial and clinical momentum than Torisel.
How strong is the temsirolimus patent estate?
The patent estate is commercially weak relative to newer oncology assets. Its age, narrow indication, mature regulatory exclusivity, and limited product differentiation reduce the probability that patent rights alone can preserve substantial revenue.
The strongest residual barriers are likely to be:
- Injectable formulation know-how
- Sterile manufacturing controls
- Product-specific stability data
- Supply-chain reliability
- Hospital procurement relationships
- Regulatory complexity for generic injection products
The weakest barriers are likely to be:
- Core clinical differentiation
- Broad market exclusivity
- Treatment-line dominance
- Physician switching costs
- Long-term growth potential
What generic launch risks exist for temsirolimus?
A generic launch could cause substantial percentage price erosion but limited absolute revenue displacement because the current market is small. The timing would depend on patent clearance, FDA approval, manufacturing readiness, supply contracts, and the willingness of hospitals to substitute the product.
A plausible launch sequence is:
- ANDA filing or 505(b)(2) development
- Patent certification review
- FDA chemistry, manufacturing, and controls assessment
- Sterile-facility inspection
- Approval or litigation
- Hospital and distributor contracting
- Progressive conversion from branded supply
The product’s low volume may support a limited number of entrants rather than a highly competitive generic market. That can preserve some pricing, particularly if manufacturing capacity is constrained.
What licensing deals and transactions involve temsirolimus?
Temsirolimus originated from Wyeth’s rapamycin-development program. Pfizer acquired Wyeth in 2009, transferring Torisel into Pfizer’s oncology portfolio.[6]
No major recent licensing transaction has materially changed the commercial ownership or strategic position of temsirolimus. The product is more likely to be managed as a mature portfolio asset than as a platform for new licensing. A transaction would have greater logic in markets where local injectable supply, hospital access, or regional registration expertise has value.
What litigation and settlement agreements affect temsirolimus?
There is no prominent current U.S. patent litigation campaign surrounding Torisel comparable with litigation involving high-revenue oral oncology drugs. The relevant legal risks are more likely to arise from:
- A future ANDA Paragraph IV filing
- Patent-term disputes
- Product liability claims
- Manufacturing or supply disputes
- Regulatory challenges involving injectable equivalence
- Contracting disputes with hospitals or distributors
No major public settlement agreement has reshaped the U.S. temsirolimus market in recent years.
What is the geographic coverage of temsirolimus?
Torisel received regulatory approvals in multiple jurisdictions, but its commercial reach is concentrated in markets with established oncology infusion infrastructure and reimbursement for targeted RCC therapies.
Geographic performance is constrained by:
- Country-specific reimbursement
- Local generic approvals
- Hospital procurement systems
- Infusion capacity
- Availability of competing immunotherapies
- Pfizer’s portfolio and distributor strategy
Emerging markets may retain demand where newer combination regimens are less accessible or less reimbursed. Those markets can extend product life but are unlikely to restore the product’s original revenue scale.
Key Takeaways
- Temsirolimus is a mature intravenous mTOR inhibitor approved for poor-risk advanced RCC.
- Its FDA approval dates to 2007, and its original exclusivity period has expired.
- Pfizer does not separately disclose current Torisel revenue in a way that supports a reliable audited product-level forecast.
- The market has shifted toward checkpoint inhibitor combinations and newer targeted therapies.
- Generic risk exists, but injectable manufacturing and a small market may limit the number of entrants.
- No biosimilar pathway applies because temsirolimus is a small molecule.
- The remaining commercial defenses are formulation, manufacturing, supply, and contracting barriers rather than strong market exclusivity.
- Temsirolimus is best characterized as a declining niche oncology product with residual value in selected treatment settings and geographies.
FAQs About Temsirolimus Market and Patent Risk
Is temsirolimus still used for kidney cancer?
Yes. It remains an FDA-approved option for adults with advanced RCC and poor-risk prognostic features, although newer immunotherapy-based regimens are commonly preferred.
Is Torisel the same drug as rapamycin?
No. Temsirolimus is a rapamycin derivative and prodrug that is converted to sirolimus in the body. It is not interchangeable with sirolimus products without regulatory approval.
Can temsirolimus be substituted with everolimus?
Not automatically. Both inhibit the mTOR pathway, but they have different formulations, labels, dosing schedules, clinical evidence, and regulatory indications.
Does temsirolimus have pediatric exclusivity?
The original FDA approval did not establish a broad pediatric indication. Any pediatric extension would depend on a specific FDA-granted exclusivity record and should be verified in the current Orange Book.
What is the biggest commercial threat to Torisel?
Therapeutic displacement by immune checkpoint inhibitor combinations and newer targeted therapies is a larger threat than generic substitution because it reduces the drug’s role in treatment decisions.
References
- U.S. Food and Drug Administration. (2007). Torisel (temsirolimus) prescribing information.
- Hudes, G., Carducci, M., Tomczak, P., et al. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine, 356(22), 2271-2281.
- National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer.
- U.S. Food and Drug Administration. (2024). Small business and industry assistance: Drug exclusivity.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Pfizer Inc. (2009). Annual report 2009.
